The expression pattern of MSLN provides an exciting opportunity for its use in targeted therapy in various types of malignant tumors, including pancreatic cancer, ovarian cancer, lung cancer, TNBC and gastric cancer. This evidence concerns the gene MSLN and familial pancreatic carcinoma.